Compare THRM & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRM | ABCL |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1993 | 2020 |
| Metric | THRM | ABCL |
|---|---|---|
| Price | $38.75 | $4.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $39.00 | $7.75 |
| AVG Volume (30 Days) | 169.4K | ★ 3.7M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $1,468,728,000.00 | $35,325,000.00 |
| Revenue This Year | $3.56 | $25.45 |
| Revenue Next Year | $2.52 | $10.07 |
| P/E Ratio | $39.37 | ★ N/A |
| Revenue Growth | N/A | ★ 7.17 |
| 52 Week Low | $22.75 | $1.89 |
| 52 Week High | $41.09 | $6.52 |
| Indicator | THRM | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 68.43 |
| Support Level | $35.86 | $3.34 |
| Resistance Level | $37.57 | $4.20 |
| Average True Range (ATR) | 0.97 | 0.21 |
| MACD | 0.11 | 0.11 |
| Stochastic Oscillator | 71.55 | 87.55 |
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.